Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Needle-Phobia Fails To Carry The Day: NICE Rejects Orencia For Second-Line Rheumatoid Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K.'s cost watchdog, the National Institute for Health and Clinical Excellence, has rejected Bristol's Orencia as a second-line therapy for rheumatoid arthritis in draft guidance, although it has changed its mind on use of the drug before.

You may also be interested in...

U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts

In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U.K.’s NHS payroll.

Sanofi-Aventis Receives Positive Final NICE Guidance On Multaq

U.K. spending watchdog recommends Multaq for atrial fibrillation and biologic therapies for rheumatoid arthritis and psoriatic arthritis, but rejects imatinib for adjuvant therapy of gastrointestinal stromal tumors.

NICE Says No To Covering Bristol’s Orencia For Rheumatoid Arthritis

Bristol will file an appeal to the decision within 10 working days, the firm tells “The Pink Sheet” DAILY.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts